AstraZeneca and Daiichi Sankyo Receive Conditional Approval for Enhertu in China

AstraZeneca and Daiichi Sankyo have received conditional approval from Chinese regulators for a new indication of their cancer therapy, Enhertu. This approval is a significant milestone for their collaboration in the Chinese market and is expected to increase patient access to the treatment. The companies are also advancing their global clinical development programs for Enhertu.